



Is Tosymra[®] right for me?

An important step to understanding how to better manage your migraine pain and associated symptoms is to have a conversation with your healthcare provider. Use this printable guide to help start the conversation with your healthcare team to see if Tosymra is right for you.

How many days do you experience migraine attacks?

- 0-5 headache days per month
- 6-14 headache days per month
- 15 or more headache days per month

Do you get pain freedom within 2 hours of taking your migraine medication?

- Always
- Most of the time
- Half of the time
- Not often (less than half of the time)

Do you get freedom of your most bothersome symptom: nausea, photophobia [light sensitivity], and phonophobia [sound sensitivity] within 2 hours of taking your migraine medication?

- Always
- Most of the time
- Half of the time
- Not often (less than half of the time)

How many migraine attacks per month does it take more than 2 hours to experience pain or most bothersome symptom relief?

- 0-2 headache attacks per month
- 3-6 headache attacks per month
- 6 or more headache attacks per month

How many migraine attacks per month do you experience nausea and vomiting?

- 0-2 headache attacks per month
- 3-6 headache attacks per month
- 6 or more headache attacks per month

Do you have any conditions that would cause gastroparesis (delayed gastric emptying) other than migraine such as usage of injectable medication for diabetes or obesity (i.e. GLP-1s), idiopathic gastroparesis, or functional dyspepsia?

- Yes
- Unsure
- No

Take a look at the answers to your questions.

Is your headache pain and associated symptoms impacting you more than you thought? Are you satisfied with the results of your current treatment? Are you interested in **adding** a nasal spray to your current migraine treatment plan?

Bring this guide to discuss with your healthcare provider and ask if Tosymra may be right for you.

Choosing the right non-oral migraine medication should be based on the speed of onset, ease of use & convenience, as well as safety & tolerability.

Tosymra[®] (sumatriptan nasal spray) 10 mg is a prescription medicine used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.

- Utilizes Intravail to enhance drug absorption across the inner lining of the nose thus allowing the medication to avoid the digestive system and minimize bad taste (dysgeusia) that has been associated with other nasal sprays.
- Ultra-rapid pain relief in as little as 15 minutes
- Portable, convenient, and easy to use



How to get Tosymra through BlinkRx

Eligible patients receive their first prescription for as little as \$0* through BlinkRx with fast, free home delivery.

1

HCP Submits Order to BlinkRx

BlinkRx will contact you directly after leaving your healthcare provider's office. You'll receive a text message from 22425 or a call from 1-844-976-3109. Click the link in the text and follow the directions to ensure you receive your prescription.

2

Respond to BlinkRx

If you miss their text or call, please call 1-833-914-3856. BlinkRx works with your insurance and automatically applies eligible savings to your co-pay. Eligible patients receive their first prescription for as little as \$0*.

3

Complete the Transaction

Finalize the BlinkRx transaction and your Tosymra[®] prescription will be shipped directly to your home.

*Restrictions and quantity limits apply. Visit tosymra.com to view complete program terms and conditions. Medicare, Medicaid and other federal and state healthcare program patients are not eligible. All marks are property of their respective owners.

INDICATION AND USAGE



Tosymra® (sumatriptan spray) is indicated for the acute treatment of migraine with or without aura in adults. Tosymra should only be used where a clear diagnosis of migraine has been established. Tosymra is not indicated for the prevention of migraine attacks or for the treatment of cluster headache.

CONTRAINDICATED IN PATIENTS WITH:

- Ischemic coronary artery disease (CAD) or coronary artery vasospasm, including Prinzmetal's angina
- Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders
- History of stroke, transient ischemic attack (TIA), or hemiplegic or basilar migraine
- Peripheral vascular disease
- Ischemic bowel disease
- Uncontrolled hypertension
- Recent (i.e., within 24 hours) use of ergotamine-containing or ergot-type medication, or another 5-HT₁ agonist
- Concurrent or recent (within 2 weeks) use of a MAO-A inhibitor
- Hypersensitivity to sumatriptan (angioedema and anaphylaxis seen)
- Severe hepatic impairment

WARNINGS AND PRECAUTIONS

- **Myocardial ischemia/infarction, Prinzmetal's angina:** These events may occur even in patients without known cardiovascular disease. Perform cardiac evaluation in triptan-naïve patients with multiple risk factors and, if satisfactory, administer first dose of Tosymra in a medically-supervised setting.
- **Arrhythmias:** Life-threatening disturbances of cardiac rhythm, including ventricular tachycardia and ventricular fibrillation leading to death, have been reported within a few hours following the administration of 5-HT₁ agonists. Discontinue Tosymra if these disturbances occur.
- **Sensations of chest/throat/neck/jaw pain, tightness, pressure, or heaviness:** Commonly occur after treatment with 5-HT₁ agonists and are usually non-cardiac in origin. Perform a cardiac evaluation in patients with cardiac risk.
- **Cerebrovascular events:** Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred in patients treated with 5-HT₁ agonists, and some have resulted in fatalities. Discontinue Tosymra if a cerebrovascular event occurs. Before treating headaches in patients not previously diagnosed as migraineurs, and in migraineurs who present with atypical symptoms, exclude other potentially serious neurological conditions.
- **Other vasospasm reactions:** 5-HT₁ agonists, including Tosymra, may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia, gastrointestinal vascular ischemia and

infarction, splenic infarction, and Raynaud's syndrome. In patients who experience symptoms or signs suggestive of a vasospastic reaction following the use of any 5-HT₁ agonist, rule out a vasospastic reaction before using Tosymra.

- **Medication overuse headache:** Overuse of acute migraine drugs may lead to exacerbation headache (medication overuse headache). Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms may be necessary.
- **Serotonin syndrome:** May occur with triptans, including Tosymra, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). The onset of symptoms usually occurs within minutes to hours of receiving a new or greater dose of a serotonergic medication. Discontinue Tosymra if serotonin syndrome is suspected.
- **Increases in blood pressure:** Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, has been reported in patients treated with 5-HT₁ agonists. Monitor blood pressure in patients treated with Tosymra.
- **Hypersensitivity reactions:** Hypersensitivity reactions, including angioedema and anaphylaxis, have occurred in patients receiving sumatriptan. Such reactions can be life threatening or fatal. Tosymra is contraindicated in patients with a history of hypersensitivity reaction to sumatriptan.
- **Seizures:** Seizures have been reported following administration of sumatriptan, with or without predisposing factors. Tosymra should be used with caution in patients with a history of epilepsy or conditions associated with a lowered seizure threshold.
- **Local irritation:** Local irritative symptoms were reported in approximately 46% of patients with Tosymra in an open-label trial which allowed repeated use of Tosymra over the course of 6 months. The most common of which were application site reaction (eg., burning sensations in the nose), dysgeusia, and throat irritation. Approximately 0.5% of the cases were reported as severe.

ADVERSE REACTIONS

The most common adverse reactions (≥5% and > placebo) with sumatriptan injection were tingling, dizziness/vertigo, warm/hot sensation, burning sensation, feeling of heaviness, pressure sensation, flushing, feeling of tightness, and numbness.

To report SUSPECTED ADVERSE REACTIONS, contact TONIX Medicines, Inc, at 1-888-869-7633 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information, including Instructions for Use, for Tosymra.